126 related articles for article (PubMed ID: 38520745)
1. Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Pasello G; Lorenzi M; Scattolin D; Del Conte A; Cecere F; Pavan A; Macerelli M; Polo V; Pilotto S; Santarpia M; Cumerlato E; Da Ros V; Targato G; Bortolami A; Bonanno L; Ferro A; Dal Maso A; Frega S; Guarneri V
Oncologist; 2024 Mar; ():. PubMed ID: 38520745
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
4. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Lorenzi M; Ferro A; Cecere F; Scattolin D; Del Conte A; Follador A; Pilotto S; Polo V; Santarpia M; Chiari R; Pavan A; Dal Maso A; Da Ros V; Targato G; Vari S; Indraccolo S; Calabrese F; Frega S; Bonanno L; Conte PF; Guarneri V; Pasello G
Oncologist; 2022 Mar; 27(2):87-e115. PubMed ID: 35641222
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
Holleman MS; Al MJ; Zaim R; Groen HJM; Uyl-de Groot CA
Eur J Health Econ; 2020 Feb; 21(1):153-164. PubMed ID: 31541309
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Khoo T; Gao L
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
10. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Trigo-Vicente C; Cortijo J
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):637-646. PubMed ID: 34602008
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
14. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
15. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A
Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
[No Abstract] [Full Text] [Related]
19. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced
Zhang D; Liu X; Shen F; Zhao D; Shi Y; Zhang H; Liu J; Gao X; Chen M; Zhao J; Zhong W; Gao J; He M; Liu Y; Yang X; Qin J; Tang Y; Mu X; Gu Y; Zhang S; Chen X; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; Li Q; Li Y; Chen J; Gao F; Jin B; Rossi A; Adachi H; Guerrera F; Husain H; Xu Y; Wang M
Transl Lung Cancer Res; 2023 Nov; 12(11):2229-2244. PubMed ID: 38090527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
